233 related articles for article (PubMed ID: 22880070)
1. The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.
Aristieta A; Azkona G; Sagarduy A; Miguelez C; Ruiz-Ortega JÁ; Sanchez-Pernaute R; Ugedo L
PLoS One; 2012; 7(8):e42652. PubMed ID: 22880070
[TBL] [Abstract][Full Text] [Related]
2. Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
Aristieta A; Ruiz-Ortega JA; Miguelez C; Morera-Herreras T; Ugedo L
Neurobiol Dis; 2016 May; 89():88-100. PubMed ID: 26852950
[TBL] [Abstract][Full Text] [Related]
3. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Sagarduy A; Llorente J; Miguelez C; Morera-Herreras T; Ruiz-Ortega JA; Ugedo L
Exp Neurol; 2016 Mar; 277():35-45. PubMed ID: 26687972
[TBL] [Abstract][Full Text] [Related]
4. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Aristieta A; Ruiz-Ortega JA; Morera-Herreras T; Miguelez C; Ugedo L
Exp Neurol; 2019 Dec; 322():113036. PubMed ID: 31425688
[TBL] [Abstract][Full Text] [Related]
5. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
6. L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus.
Soghomonian JJ
Eur J Neurosci; 2006 May; 23(9):2395-403. PubMed ID: 16706847
[TBL] [Abstract][Full Text] [Related]
7. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
8. Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
Marin C; Bonastre M; Mengod G; Cortés R; Rodríguez-Oroz MC; Obeso JA
Exp Neurol; 2013 Dec; 250():304-12. PubMed ID: 24140562
[TBL] [Abstract][Full Text] [Related]
9. High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease.
Oueslati A; Sgambato-Faure V; Melon C; Kachidian P; Gubellini P; Amri M; Kerkerian-Le Goff L; Salin P
J Neurosci; 2007 Feb; 27(9):2377-86. PubMed ID: 17329435
[TBL] [Abstract][Full Text] [Related]
10. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Gil S; Park C; Lee J; Koh H
Cell Mol Neurobiol; 2010 Aug; 30(6):817-25. PubMed ID: 20232137
[TBL] [Abstract][Full Text] [Related]
11. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
12. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
[TBL] [Abstract][Full Text] [Related]
13. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
14. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
15. Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain.
Kim E; Frouni I; Shaqfah J; Bédard D; Huot P
J Chem Neuroanat; 2024 Jul; 138():102422. PubMed ID: 38657828
[TBL] [Abstract][Full Text] [Related]
16. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
[TBL] [Abstract][Full Text] [Related]
17. Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.
Quintana A; Sgambato-Faure V; Savasta M
Neurobiol Dis; 2012 Dec; 48(3):379-90. PubMed ID: 22759925
[TBL] [Abstract][Full Text] [Related]
18. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
[TBL] [Abstract][Full Text] [Related]
19. High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats.
Lacombe E; Carcenac C; Boulet S; Feuerstein C; Bertrand A; Poupard A; Savasta M
Eur J Neurosci; 2007 Sep; 26(6):1670-80. PubMed ID: 17822436
[TBL] [Abstract][Full Text] [Related]
20. Ondansetron, a highly selective 5-HT
Kwan C; Frouni I; Bédard D; Hamadjida A; Huot P
Eur J Pharmacol; 2020 Mar; 871():172914. PubMed ID: 31926127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
